GIP and metabolic dysfunction-associated steatohepatitis: Beyond the heart and kidneys, SGLT2is, and particularly GLP-1RAs and GIP/GLP-1RAs, have shown promise in MASLD (formerly known as non-alcoholic fatty liver disease—NAFLD) and MASH (formerly known as non-alcoholic steatohepatitis—NASH).